Editor's note: This story was updated on Feb. 23 to include more info about the company's lead treatment. Latigo Biotherapeutics, a Thousand Oaks-based biotech firm that was originally founded by Westlake Village BioPartners, emerged from stealth mode on Feb. 14, announcing $135 million in Series A financing. Latigo is a clinical-stage biotechnology company looking to
Latigo Biotherapeutics, a Thousand Oaks-based biotech firm that was originally founded by Westlake Village BioPartners, emerged from stealth mode on Feb. 14, announcing $135 million in Series A financing. Latigo is a clinical-stage biotechnology company looking to develop non-opioid pain medicines that target pain at its source, according to a press release. Proceeds from the
Latigo Biotherapeutics emerged from
stealth mode on Wednesday and said it had raised $135 million in
series A funding to advance clinical trials of its non-opioid
pain treatments, including a drug.